Comorbidity and treatment decision-making in elderly non-Hodgkin's lymphoma patients: a survey among haematologists

被引:0
作者
van der Poel, M. W. M. [1 ]
Mulder, W. J. [1 ]
Ossenkoppele, G. J. [2 ]
Maartense, E. [3 ]
Wijermans, P. [4 ]
Hoogendoorn, M. [5 ]
Schouten, H. C. [1 ]
机构
[1] Maastricht Univ, Med Ctr, Dept Internal Med, Maastricht, Netherlands
[2] Vrije Univ Amsterdam, Med Ctr, Dept Haematol, Amsterdam, Netherlands
[3] Reinier De Graaf Hosp, Dept Internal Med, Delft, Netherlands
[4] Haga Hosp, Dept Haematol, The Hague, Netherlands
[5] Med Ctr Leeuwarden, Dept Haematol, Leeuwarden, Netherlands
关键词
Comorbidity; elderly; non-Hodgkin's lymphoma; survey; B-CELL LYMPHOMA; COMPREHENSIVE GERIATRIC ASSESSMENT; CO-MORBIDITY; 1ST-LINE CHEMOTHERAPY; PROGNOSTIC IMPACT; CLINICAL-TRIALS; OLDER PATIENTS; CANCER; RITUXIMAB; JUDGMENT;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Elderly patients with non-Hodgkin's lymphoma (NHL) are often not treated with standard immunochemotherapy and this might have a negative impact on their survival. Little is known about the determinants that play a role in treatment decision-making of clinicians regarding elderly patients with NHL. The objective of this study was to gain more insight into these determinants. Methods: A survey was conducted amongst haematologists in the Netherlands. The survey contained questions about comorbidity, polypharmacy, social setting, nutritional status, depression, mild cognitive impairment, dementia, activities of daily living (ADL) and instrumental activities of daily living (IADL) in relation to treatment decisions in elderly NHL patients. Results: Of all comorbidities, respondents designated cognitive disorders and cardiovascular comorbidity as the most important factors when assessing whether an older patient with NHL is eligible for curative treatment. Also in decreasing degree of importance ADL, IADL and depressive disorder are frequently included in treatment decision-making. Almost half of the respondents feel that treatment of the elderly person is complicated as a result of a lack of scientific evidence. Conclusion: Haematologists are aware of coexisting problems in elderly patients and they frequently take comorbidities, cognitive disorders and functional status into consideration in treatment decision-making. Future studies are needed to determine the exact role that these factors should play in the treatment of elderly patients. Furthermore, haematologists feel that treatment of the elderly is complicated and there is a lack of scientific evidence, and therefore older adults should be better represented in clinical trials.
引用
收藏
页码:165 / 169
页数:5
相关论文
共 30 条
  • [1] Predictive value of geriatric assessment for patients older than 70 years, treated with chemotherapy
    Aaldriks, A. A.
    Maartense, E.
    le Cessie, S.
    Giltay, E. J.
    Verlaan, H. A. C. M.
    van der Geest, L. G. M.
    Kloosterman-Boele, W. M.
    Peters-Dijkshoorn, M. T.
    Blansjaar, B. A.
    van Schaick, H. W.
    Nortier, J. W. R.
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2011, 79 (02) : 205 - 212
  • [2] Barriers to inclusion of older adults in randomised controlled clinical trials on Non-Hodgkin's lymphoma: A systematic review
    Bellera, Carine
    Praud, Delphine
    Petit-Moneger, Aurelie
    McKelvie-Sebileau, Pippa
    Soubeyran, Pierre
    Mathoulin-Pelissier, Simone
    [J]. CANCER TREATMENT REVIEWS, 2013, 39 (07) : 812 - 817
  • [3] Boslooper K, 2013, LEUK LYMPHOMA
  • [4] CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
    Coiffier, B
    Lepage, E
    Brière, J
    Herbrecht, R
    Tilly, H
    Bouabdallah, R
    Morel, P
    Van den Neste, E
    Salles, G
    Gaulard, P
    Reyes, F
    Gisselbrecht, C
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) : 235 - 242
  • [5] Two sides of the medallion: poor treatment tolerance but better survival by standard chemotherapy in elderly patients with advanced-stage diffuse large B-cell lymphoma
    de Schans, S. A. M. van
    Wymenga, A. N. M.
    van Spronsen, D. J.
    Schouten, H. C.
    Coebergh, J. W. W.
    Janssen-Heijnen, M. L. G.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 (05) : 1280 - 1286
  • [6] Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma:: A study by the groupe d'Etude des lymphomes de l'adulte
    Feugier, P
    Van Hoof, A
    Sebban, C
    Solal-Celigny, P
    Bouabdallah, R
    Fermé, C
    Christian, B
    Lepage, E
    Tilly, H
    Morschhauser, F
    Gaulard, P
    Salles, G
    Bosly, A
    Gisselbrecht, C
    Reyes, F
    Coiffier, B
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (18) : 4117 - 4126
  • [7] Does a geriatric oncology consultation modify the cancer treatment plan for elderly patients?
    Girre, Veronique
    Falcou, Marie-Christine
    Gisselbrecht, Mathilde
    Gridel, Genevieve
    Mosseri, Veronique
    Bouleuc, Carole
    Poinsot, Rollon
    Vedrine, Lionel
    Ollivier, Liliane
    Garabige, Valerie
    Pierga, Jean-Yves
    Dieras, Veronique
    Mignot, Laurent
    [J]. JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES, 2008, 63 (07): : 724 - 730
  • [8] Comparative Effectiveness and Cost of Adding Rituximab to First-Line Chemotherapy for Elderly Patients Diagnosed With Diffuse Large B-Cell Lymphoma
    Griffiths, Robert I.
    Gleeson, Michelle L.
    Mikhael, Joseph
    Dreyling, Martin H.
    Danese, Mark D.
    [J]. CANCER, 2012, 118 (24) : 6079 - 6088
  • [9] Impact and Feasibility of a Comprehensive Geriatric Assessment in the Oncology Setting A Pilot Study
    Horgan, Anne M.
    Leighl, Natasha B.
    Coate, Linda
    Liu, Geoffrey
    Palepu, Prakruthi
    Knox, Jennifer J.
    Perera, Nicole
    Emami, Marjan
    Alibhai, Shabbir M. H.
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2012, 35 (04): : 322 - 328
  • [10] Prognostic impact of increasing age and co-morbidity in cancer patients: A population-based approach
    Janssen-Heijnen, MLG
    Houterman, S
    Lemmens, VEPP
    Louwman, MWJ
    Maas, HAAM
    Coebergh, JWW
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2005, 55 (03) : 231 - 240